Raleigh Capital Management’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Raleigh Capital Management’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$38.5K	Sell	389 -8,270	-96%	-$745K	0.01%	295
2026 Q1	$751K	Buy	8,659 +8,658	+865,800%	+$758K	0.26%	99
2025 Q4	$85	Hold	1	–	–	﹤0.01%	467
2025 Q3	$72	Hold	1	–	–	﹤0.01%	439
2025 Q2	$65	Hold	1	–	–	﹤0.01%	601
2025 Q1	$70	Hold	1	–	–	﹤0.01%	542
2024 Q4	$65	Hold	1	–	–	﹤0.01%	1010
2024 Q3	$80	Sell	1 -25,819	-100%	-$1.8M	﹤0.01%	980
2024 Q2	$1.71M	Buy	+25,820	New	+$1.69M	0.73%	37

Other funds holding IHE

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

IWS

Insight Wealth Strategies San Ramon, California $1.02B AUM 38% 1-Year Est. Return

Raleigh Capital Management's IHE Position: Q2 2026 in Review

Raleigh Capital Management reduced its iShares US Pharmaceuticals ETF (IHE) stake by 96% in Q2 2026, selling an estimated $745K and leaving 389 shares worth $38.5K. The position accounts for 0.01% of the portfolio, ranked #295.

Raleigh Capital Management first reported a position in IHE in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.71M in Q2 2024. 210 funds tracked by Wall St. Rank hold IHE as of Q2 2026.

Raleigh Capital Management held 389 shares of iShares US Pharmaceuticals ETF worth $38.5K as of Q2 2026.
Raleigh Capital Management sold 8,270 iShares US Pharmaceuticals ETF shares in Q2 2026, an estimated $745K.
iShares US Pharmaceuticals ETF made up 0.01% of Raleigh Capital Management's portfolio in Q2 2026, its #295 holding.
Raleigh Capital Management first reported a position in iShares US Pharmaceuticals ETF in Q2 2024 and has held it in 9 quarters since.
Raleigh Capital Management's iShares US Pharmaceuticals ETF position peaked at $1.71M in Q2 2024.
210 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q2 2026.

Based on Raleigh Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.